New hope for Drug-Resistant TB: shorter, safer treatment on the horizon?

NCT ID NCT06441006

Recruiting now Disease control Sponsor: University of California, San Francisco Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 24, 2026 · Updated 1 time

Summary

This study tests whether a shorter treatment regimen (13-24 weeks) using a combination of drugs (bedaquiline, linezolid, pretomanid, and moxifloxacin) works as well as the standard longer treatment for people with a type of drug-resistant tuberculosis. About 400 adults with fluoroquinolone-susceptible multidrug-resistant TB will be randomly assigned to different treatment lengths. The goal is to find a regimen that cures patients with fewer side effects and less time on medication.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: bedaquiline, linezolid, pretomanid, moxifloxacin
What this could lead to: If successful, this trial could lead to shorter, more effective treatment regimens for multidrug-resistant tuberculosis, reducing side effects and improving cure rates.
What could go wrong: This is an early-to-mid-stage trial with only 400 participants, so results may not apply to all patients. There are risks of serious side effects from the drugs, and the shorter treatment may not work as well as standard care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FLUOROQUINOLONE-SUSCEPTIBLE MULTIDRUG-RESISTANT/RIFAMPICIN-RESISTANT PULMONARY TUBERCULOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

multidrug-resistant tuberculosis pulmonary tuberculosis rifampicin-resistant tuberculosis tuberculosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TUBERCULOSIS, MDR TUBERCULOSIS, MULTIDRUG-RESISTANT TUBERCULOSIS, PULMONARY

Contacts and locations

Locations

Hanoi Lung Hospital
NOT_YET_RECRUITING

Hanoi, Vietnam
Hospital Nacional Sergio E. Bernales
NOT_YET_RECRUITING

Lima, Peru
Institute of Chest Diseases
NOT_YET_RECRUITING

Kotri, Pakistan
Mulago National Referral Hospital
RECRUITING

Kampala, Uganda
National Center for Communicable Diseases
RECRUITING

Ulaanbaatar, Mongolia
Policlínico SES
RECRUITING

Lima, Peru

More trials for these conditions

Other studies related to the condition(s) this trial covers.